Efficacy and tolerability of chitin-glucan combined with simethicone (GASTRAP® DIRECT) in irritable bowel syndrome: A prospective, open-label, multicenter study

doi:10.4292/wjgpt.v15.i3.90757

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2192)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-8) series, Tables (1-5) series.

Item

Count

PDF

WORD

HTML

1146

Figures (1-8)

115

Tables (1-5)

131

Sum=1447

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

126

Download

338

Sum=464

Publishing Process of This Article

Item

Count

Browse

Download

157

Sum=201

May 28, 2024 (publication date) through Nov 14, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Gastrointest Pharmacol Ther. May 28, 2024; 15(3): 90757
Published online May 28, 2024. doi: 10.4292/wjgpt.v15.i3.90757

Table 4 Symptom relief at week 4 of GASTRAP^® DIRECT treatment in patients with IBS having prevalent constipation, diarrhea, and mixed irritable bowel syndrome

Symptom relief at W4	IBS-C (%)	IBS-D (%)	IBS-M (%)
Abdominal pain
Unchanged	42	27	34
Relief (very much, considerable)	58 (50, 8)	73 (46, 27)	66 (48, 18)
Bloating
Unchanged	42	32	31
Relief (very much, considerable)	58 (46, 12)	68 (41, 27)	69 (53, 16)
Abdominal distension
Unchanged	46	50	39
Relief (very much, considerable)	54 (39, 15)	50 (36, 14)	61 (39, 21)

W: Weeks; IBS: Irritable bowel syndrome; IBS-C: IBS patients with prevalent constipation; IBS-D: IBS patients with prevalent diarrhea; IBS-M: IBS patients with mixed symptoms.

Citation: Talbodec N, Le Roy P, Fournier P, Lesage B, Lepoutre E, Castex F, Godchaux JM, Vandeville L, Bismuth B, Lesage X, Bayart P, Genin M, Rousseaux C, Maquet V, Modica S, Desreumaux P, Valibouze C. Efficacy and tolerability of chitin-glucan combined with simethicone (GASTRAP^® DIRECT) in irritable bowel syndrome: A prospective, open-label, multicenter study. World J Gastrointest Pharmacol Ther 2024; 15(3): 90757
URL: https://www.wjgnet.com/2150-5349/full/v15/i3/90757.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v15.i3.90757